[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637154":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":51,"collaborators":26,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":26,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":82,"whyStopped":26,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Dhaka Medical College","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group-A","EXPERIMENTAL","Drug: Digestive enzyme 325mg + first line treatment This group will get digestive enzyme 325 mg 3 times daily along with first line treatment (PPI 20 mg twice daily and Prokinetics such domperidone 10mg three time daily) for 1 month",[13],"Drug: Digestive enzyme 325mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Group-B","ACTIVE_COMPARATOR","Drug: First line treatment only This group will get first line treatment only ( PPI 20 mg twice daily and prokinetics such as domperidone 10 mg 3 times daily) for 1 month",[19],"Drug: PPI 20 mg + Domperidone 10 mg",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Digestive enzyme 325mg","Digestive enzyme will be given to group A patient",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"PPI 20 mg + Domperidone 10 mg","Group B patient will get first line treatment only for 1 month",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Rakibul Mostafa","CONTACT","+8801837031585","rakibmasuk96@gmail.com",[38],{"facility":5,"status":26,"city":39,"state":26,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Dhaka","1000","Bangladesh","BD",{"type":44,"coordinates":45},"Point",[46,47],90.40744,23.7104,{"lat":47,"lon":46},[50],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"type":52,"investigatorFullName":33,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Principle Investigator","100637154","phase-4-effect-of-digestive-enzymes-as-add-on-therapy-on-patients-with-functional-dyspepsia-100637154",false,"NCT07578402","Effect of Digestive Enzymes as Add on Therapy on Patients With Functional Dyspepsia.","Effect of Digestive Enzymes as Add on Therapy on Patients With Functional Dyspepsia - A Randomised, Open Label Trial","Inclusion Criteria:\n\n* Age 18 years or more\n* Patients with FD diagnosed according to ROME IV criteria\n\nExclusion Criteria:\n\n* Structural lesion in endoscopy and positive H. pylori status\n* History of malignancy, liver and biliary tract disease, diabetes mellitus, chronic kidney disease, thyroid disorders\n* Psychiatric disorders\n* Previous history gastrointestinal surgery\n* Any history of hypersensitivity, adverse effect, or ineffectiveness with digestive enzyme\n* Pregnancy and breastfeeding.",true,"ALL","18 Years","70 Years",{"count":66,"type":67},120,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","The goal of this clinical trial is to assess the effect of digestive enzymes in improving dyspeptic symptoms in patients with functional dyspepsia. It will also assess about the safety of drug by recording the patient reported adverse events. The main questions it aims to answer are:\n\nDoes drug digestive enzymes has any effect on patients with functional dyspepsia? What medical problems do participants have when taking drug digestive enzymes? Researcher will compare drug digestive enzymes to a control group taking standard first line treatment only.\n\nParticipants will:\n\nTake drug digestive enzymes 325 milligrams 3 times daily, every day for 4 weeks along with standard first line treatment. A second group will be taken as control arm who will be kept on standard first line treatment only for 4 weeks. They will visit the hospital 2 weekly, and their symptoms will be assessed by a 5-point Likert Scale at baseline, week 2 and 4. Additionally, patient reported adverse events will be documented.",[73,74,75,76],"Dyspepsia","Functioanl Dyspepsia","Epigastric Pain Syndrome","Epigastric Fullness",[73,78,79,80,81],"Post parendial distress syndrome (PPDS)","Epigastric pain syndrome (EPS)","Functional dyspepsia (FD)","Disorder of gut brain interaction (DGBI)","NOT_YET_RECRUITING","2026-05-05",{"date":85,"type":86},"2026-05-11","ACTUAL",{"date":88,"type":67},"2026-05-15",{"date":90,"type":67},"2027-02-28",{"name":33,"class":6},1]